Robert D. Schwab

Robert D. Schwab

Auto-generated profile, based on publicly available information

Robert D. Schwab

University of Pennsylvania 4 Department of Medicine, Perelman School of Medicine Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Immunity
Verified
Journal Article
Closed access
Avery Posey, Jr.Avery Posey, Jr.
Avery Posey, Jr.
RSRobert D. Schwab
Robert D. Schwab
ABAlina C. Boesteanu
Alina C. Boesteanu
CSCatharina Steentoft
Catharina Steentoft
UMUlla Mandel
Ulla Mandel
CJCarl H. June
Carl H. June

3 February 2026 in Circulation
Verified
Journal Article
Closed access
RSRobert D. Schwab
Robert D. Schwab
DDDavid Degaramo
David Degaramo
SHSeok Jae Hong
Seok Jae Hong
XBXin Bi
Xin Bi
AFAisha Faruqi
Aisha Faruqi
Avery Posey, Jr.Avery Posey, Jr.
Avery Posey, Jr.
BACKGROUND: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a need for new medical therapies, especially for patients who are not eligible for percutaneous intervention. Atherosclerosis is driven by the accumulation of low-density lipoprotein and the formation of foam cells, accompanied by oxidative stress and the accumulation of oxidized low-density lipoprotein (OxLDL), a proinflammatory molecule. Lowering low-density lipoprotein levels is the mainstay of current treatment, along with blood pressure control and lifestyle changes, but to date, it has not been feasible to specifically target inflammatory pathways contributing to plaque development without considerable systemic side effects. Over the past decade, chimeric antigen receptor T cells have been used to treat cancer, resolve cardiac fibrosis, and restore immune balance in autoimmune diseases. In some instances, regulatory T cells endowed with chimeric antigen receptor (CAR Tregs) have been developed to treat autoimmunity through antigen-specific immunosuppression. METHODS: Using an inducible regulatory T cell platform, we created an anti-OxLDL–specific CAR Treg therapy and evaluated cell- and cytokine-mediated immunosuppression to reduce macrophage foam cell formation in vitro. We then tested murine anti-OxLDL CAR Tregs in immunocompetent mouse models of hyperlipidemia and atherosclerosis. RESULTS: Anti-OxLDL CAR Tregs reduced macrophage foam cell formation in vitro and significantly inhibited atherosclerotic plaque formation in vivo in immunocompetent mouse models. CONCLUSIONS: Anti-OxLDL CAR Tregs mitigate inflammation and plaque deposition associated with OxLDL and may offer a new therapeutic option for atherosclerosis.

16 November 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SBStephen Joseph Bagley
Stephen Joseph Bagley
RSRobert D. Schwab
Robert D. Schwab
ENErnest Nelson
Ernest Nelson
AVAngela N. Viaene
Angela N. Viaene
ZBZev A. Binder
Zev A. Binder
MNMacLean P. Nasrallah
MacLean P. Nasrallah

1 April 2016 in Seminars in Oncology
Verified
Journal Article
Open access
JFJoseph A. Fraietta
Joseph A. Fraietta
RSRobert D. Schwab
Robert D. Schwab
MMMarcela V. Maus
Marcela V. Maus
Adoptive cell immunotherapy for the treatment of chronic lymphocytic leukemia (CLL) has heralded a new era of synthetic biology. The infusion of genetically engineered, autologous chimeric antigen receptor (CAR) T cells directed against CD19 expressed by normal and malignant B cells represents a novel approach to cancer therapy. The results of recent clinical trials of CAR T cells in relapsed and refractory CLL have demonstrated long-term disease-free remissions, underscoring the power of harnessing and redirecting the immune system against cancer. This review will briefly summarize T-cell therapies in development for CLL disease. We discuss the role of T-cell function and phenotype, T-cell culture optimization, CAR design, and approaches to potentiate the survival and anti-tumor effects of infused lymphocytes. Future efforts will focus on improving the efficacy of CAR T cells for the treatment of CLL and incorporating adoptive cell immunotherapy into standard medical management of CLL.

10 November 2019
Verified
Book Chapter
Closed access
PDF file
RSRobert D. Schwab
Robert D. Schwab
DBDarel Martínez Bedoya
Darel Martínez Bedoya
TKTiffany R. King
Tiffany R. King
BLBruce L. Levine
Bruce L. Levine
Avery Posey, Jr.Avery Posey, Jr.
Avery Posey, Jr.

29 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
HMHeather C. Milbar
Heather C. Milbar
ACAvrom Caplan
Avrom Caplan
RSRobert D. Schwab
Robert D. Schwab
ACAlexandra J. Coromilas
Alexandra J. Coromilas
EBEmily Baumrin
Emily Baumrin
MRMisha Rosenbach
Misha Rosenbach